About Us


Indapta is a biotechnology company seeking to harness the natural power of the immune system to fight hematologic and solid cancers with our universal G-NK cell platform. Headquartered in San Francisco, Indapta was founded in 2017 by Guy DiPierro along with Ronald Martell and scientists at the University of California, Davis, and Stanford University. The company has developed allogeneic FcRγ-deficient natural killer cells, known as G-NK cells. Indapta is working to bring this off-the-shelf cellular therapy to cancer patients to address the limitations of currently available immunotherapies.

 

G-NK cell therapy is an off-the-shelf solution, eliminating the need for a patient-specific therapy.

G-NK cell therapy is combined with FDA-approved tumor-targeting antibodies.

Leadership


Guy DiPierro

Guy DiPierro

Chief Executive Officer and Founder

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

Ronald Martell

Ronald Martell

Executive Chairman and Co-Founder

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

Dov Goldstein

Dov Goldstein

Chief Business Officer and Chief Financial Officer

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

Lori Kunkel

Lori Kunkel

Head Strategic Clinical Advisor

Austin Bigley, PhD

Austin Bigley, PhD

Senior Director, Research and Development

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

Catherine Polizzi

Catherine Polizzi

Chief Intellectual Property Counsel at Morrison & Foerster

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

Kathy Leach

Kathy Leach

Manufacturing Advisor

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

Elana Van Oudenaren

Elana Van Oudenaren

Head of Quality

Nina Shah, M.D.

Associate Professor, Department of Medicine, University of California, San Francisco

Sungjin Kim, Ph.D.

Scientific Founder, Indapta; Associate Professor, Department of Medical Microbiology and Immunology, University of California, Davis

John Sunwoo, M.D.

Scientific Founder, Indapta; Professor, Stanford University School of Medicine

Todd A. Fehniger, M.D., Ph.D.

Associate Professor, Department of Medicine, Oncology Division, Washington University School of Medicine

Vaughn Smider, M.D., Ph.D.

Associate Professor, Department of Molecular Medicine, Scripps Research Institute

Arun Wiita, M.D., Ph.D.

Associate Professor, Department of Laboratory Medicine, University of California, San Francisco

Product Portfolio


Cancer is the leading cause of death worldwide. Current therapies are suboptimal, frequently ineffective and often cause significant side effects.

Immunotherapies are a formidable new mechanism to fight cancer. Designed to boost the immune response, immunotherapies such as G-NK therapy were developed to address the limitations of currently available autologous T-cell therapies.

Natural killer (NK) cells are the immune system’s first responders against cancer and pathogens that cause infectious diseases. Indapta Therapeutics believes that NK cell therapy has immense potential to be used in the development of cutting-edge cancer therapies for various tumor types.

Indapta’s NK cell therapy product stems from a naturally occurring and highly potent type of NK cell, known as G-NK cells. Engineered by nature to fight cancer, G-NK cells have enhanced anti-tumor activity due to an epigenetic change resulting in the absence of the FcRγ chain. Indapta’s proprietary expansion process improves the functionality, reproducibility and persistence of these G-NK cells without the need for artificial genetic engineering.

Indapta then combines these G-NK cells with FDA-approved antibodies to improve and enhance the inherent power of the immune system to target and destroy tumor cells, while potentially offering a tolerable safety profile. Indapta’s universal, allogeneic G-NK cell therapy is intended to be used in combination with the numerous FDA-approved antibodies to treat a variety of cancers.

Our Science


Indapta Therapeutics is developing a universal, allogeneic G-NK cell therapy designed to substantially improve the cytotoxicity of antibody therapy in multiple cancers. Indapta has enhanced the anti-tumor activity of its G-NK cell therapy via specific G-NK cell subset selection and its proprietary manufacturing process. This produces an NK cell therapy that demonstrates higher efficacy, persistence and enhanced cryopreservation than standard monoclonal antibody therapy or standard monoclonal antibody therapy combined with conventional NK cells.

Engagement of Indapta’s G-NK cell therapy with an antibody bound to a tumor target initiates the release of dramatically more cancer killing compounds than that produced by conventional NK cells. This allows for increased efficacy and potentially less frequent dosing. Indapta’s off-the-shelf G-NK cell therapy is further differentiated in that it is a cell banked product with low variability.

Recent News


August 10
2021
Indapta Therapeutics Announces New Preclinical Data Demonstrating Proprietary G-NK Cells Enhance Efficacy of Monoclonal Antibodies in Multiple Myeloma

Read More

February 03
2021
Indapta Therapeutics Announces Key Management Team Appointments to Advance into Clinical Trials in 2021

Read More

October 28
2020
Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics Announce Investment to Advance Clinical Development of Natural Killer Cell Therapy

Read More

August 29
2020
Indapta Therapeutics Appoints Dov Goldstein, M.D., Chief Financial and Business Officer

Read More

July 09
2020
Indapta Therapeutics Provides Corporate Update

Read More

January 10
2020
Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy

Read More

For additional information, please contact   info@indapta.com

Hide picture